CN109952304A - 一类抑制并降解cdk的化合物 - Google Patents

一类抑制并降解cdk的化合物 Download PDF

Info

Publication number
CN109952304A
CN109952304A CN201880004082.3A CN201880004082A CN109952304A CN 109952304 A CN109952304 A CN 109952304A CN 201880004082 A CN201880004082 A CN 201880004082A CN 109952304 A CN109952304 A CN 109952304A
Authority
CN
China
Prior art keywords
substituent group
alkyl
integer
independently selected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004082.3A
Other languages
English (en)
Other versions
CN109952304B (zh
Inventor
舒永志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Meizer Pharmaceuticals Co ltd
Original Assignee
Shanghai Meizer Pharmaceuticals Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Meizer Pharmaceuticals Co ltd filed Critical Shanghai Meizer Pharmaceuticals Co ltd
Publication of CN109952304A publication Critical patent/CN109952304A/zh
Application granted granted Critical
Publication of CN109952304B publication Critical patent/CN109952304B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一类抑制并降解CDK的化合物，具体地，本发明提供了一种如下式I所示的化合物；其中，各基团的定义如说明书中所述。本发明的化合物具有很好的周期蛋白依赖性激酶CDK抑制活性，可以用于制备治疗CDK活性相关的疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880004082.3A 2017-09-17 2018-09-14 一类抑制并降解cdk的化合物 Active CN109952304B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710837228.XA CN109516989B (zh) 2017-09-17 2017-09-17 一类抑制并降解cdk的化合物
CN201710837228X 2017-09-17
PCT/CN2018/105713 WO2019052535A1 (zh) 2017-09-17 2018-09-14 一类抑制并降解cdk的化合物

Publications (2)

Publication Number Publication Date
CN109952304A true CN109952304A (zh) 2019-06-28
CN109952304B CN109952304B (zh) 2021-08-24

Family

ID=65722403

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710837228.XA Active CN109516989B (zh) 2017-09-17 2017-09-17 一类抑制并降解cdk的化合物
CN201880004082.3A Active CN109952304B (zh) 2017-09-17 2018-09-14 一类抑制并降解cdk的化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710837228.XA Active CN109516989B (zh) 2017-09-17 2017-09-17 一类抑制并降解cdk的化合物

Country Status (3)

Country Link
US (1) US11236090B2 (zh)
CN (2) CN109516989B (zh)
WO (1) WO2019052535A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109422733A (zh) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物
IL275490B2 (en) 2017-12-22 2024-05-01 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
EP3827000A4 (en) * 2018-07-23 2022-03-30 Dana-Farber Cancer Institute, Inc. DEGRADATION OF CYCLINE DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH LIGASE E3 LIGAND AND METHODS OF USE
CN110305126A (zh) * 2019-06-19 2019-10-08 浙江省医学科学院 一种基于crbn配体诱导cdk4/6降解的化合物及其制备方法、药物组合物和应用
CA3186548A1 (en) * 2020-07-21 2022-01-27 Song Hee Lee Compound for androgen receptor degradation, and pharmaceutical use thereof
WO2023177451A1 (en) * 2022-03-18 2023-09-21 EnhancedBio Inc. Compounds and methods for the targeted degradation of cyclin dependent kinases
WO2023207875A1 (en) * 2022-04-25 2023-11-02 Onquality Pharmaceuticals China Ltd. Cdk inhibitors, pharmaceutical compositions, and therapeutic applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014063061A1 (en) * 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2016015605A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014063061A1 (en) * 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2016015605A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer

Also Published As

Publication number Publication date
CN109516989A (zh) 2019-03-26
CN109952304B (zh) 2021-08-24
CN109516989B (zh) 2021-12-31
US20200216450A1 (en) 2020-07-09
US11236090B2 (en) 2022-02-01
WO2019052535A1 (zh) 2019-03-21

Similar Documents

Publication Publication Date Title
CN109952304A (zh) 一类抑制并降解cdk的化合物
CN109422752A (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
CN109963844A (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
US10406166B2 (en) Antimicrobial compound
TWI710552B (zh) 作為神經元組織胺受體－３拮抗劑之化合物及其用途
ES2929526T3 (es) Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
WO2018175311A1 (en) Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
CN110317192A (zh) 一类具有降解雄激素受体活性的化合物
AU2007288281A1 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
JP2021527112A (ja) ニューロキニン−１受容体アンタゴニストとしての化合物およびその使用
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
TWI415613B (zh) Anti-cancer agent resistance to overcome the agent
CN109963853A (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CN109937203A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
TW201831484A (zh) 巴瑞克替尼（Ｂａｒｉｃｉｔｉｎｉｂ）磷酸鹽晶型Ｄ及其藥物組合物
TW202035406A (zh) 作為cdk-hdac雙通路抑制劑的雜環化合物
CN109476667A (zh) Ttk抑制剂的固体形式
WO2022159491A1 (en) Rifamycin analogs
CN116514902A (zh) 氘代拟肽类化合物及其用途
WO2023192864A2 (en) Covalent parp16 inhibitors
TW201406377A (zh) 抗癌劑之抗性克服劑
TW200539884A (en) New alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments
JPH02279673A (ja) キノロン誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant